1.14

5.00% -0.06

Coherus Oncology Inc (CHRS)

Overview News Price History Option Chain Financials Why CHRS Down? Discussions Forecast

Coherus Oncology Inc stock is traded at $1.14, with a volume of 809.14K. It is down -5.00% in the last 24 hours and down -18.57% over the past month. Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Previous Close:

$1.20

Open:

$1.2

24h Volume:

809.14K

Relative Volume:

0.82

Market Cap:

$176.13M

Revenue:

$46.88M

Net Income/Loss:

$-172.66M

P/E Ratio:

-0.9149

EPS:

-1.2461

Net Cash Flow:

$-170.57M

1W Performance:

-8.06%

1M Performance:

-18.57%

6M Performance:

-29.19%

1Y Performance:

+8.57%

1-Day Range:

$1.13

$1.2001

1-Week Range:

$1.13

$1.2599

52-Week Range:

$1.03

$2.6158

Coherus Oncology Inc Stock (CHRS) Company Profile

Name

Coherus Oncology Inc

Sector

Healthcare (1089)

Industry

Biotechnology (604)

Phone

(650) 649-3530

Address

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

Employee

145

Twitter

@coherus_bio

Next Earnings Date

2026-08-05

Latest SEC Filings

CHRS's Discussions on Twitter

Compare CHRS vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CHRS Coherus Oncology Inc	1.14	185.40M	46.88M	-172.66M	-170.57M	-1.2461
VRTX Vertex Pharmaceuticals Inc	515.50	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	806.71	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	991.46	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.24	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.25	39.31B	5.76B	514.49M	1.10B	4.4813

Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-23-26	Initiated	Oppenheimer	Outperform
Sep-04-25	Upgrade	Maxim Group	Hold → Buy
Aug-16-24	Downgrade	UBS	Buy → Neutral
Nov-17-23	Initiated	Robert W. Baird	Outperform
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy
May-01-23	Initiated	Truist	Buy
Mar-28-23	Upgrade	UBS	Neutral → Buy
Jun-14-22	Initiated	UBS	Neutral
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral
Jul-16-20	Initiated	BofA Securities	Neutral
Apr-17-20	Initiated	SunTrust	Buy
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	H.C. Wainwright	Buy
Aug-02-19	Reiterated	Maxim Group	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-07-19	Initiated	H.C. Wainwright	Buy
Aug-28-18	Initiated	H.C. Wainwright	Buy
Mar-09-18	Reiterated	Maxim Group	Buy
Aug-08-17	Reiterated	JP Morgan	Overweight
Jun-13-17	Reiterated	Maxim Group	Buy
May-05-17	Initiated	BMO Capital Markets	Outperform
Oct-19-16	Initiated	Robert W. Baird	Outperform
Sep-07-16	Initiated	Maxim Group	Buy
Jul-27-16	Initiated	Citigroup	Buy
Jan-20-16	Initiated	Credit Suisse	Outperform

View All

Coherus Oncology Inc Stock (CHRS) Latest News

01:17 AM

Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com Nigeria

Aug 07, 2026

Coherus Oncology Price Target Cut to $10.00/Share From $12.00 by Guggenheim - Moomoo

Aug 07, 2026

Aug 06, 2026

H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Aug 06, 2026

Coherus Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 06, 2026

Coherus Oncology (CHRS) Drops 7.24% to $1.34, Pressing Key Support at $1.27Value ETF - dars.gov.et

Aug 06, 2026